Adjuvant Chemotherapy for High-Grade Undifferentiated Pleomorphic Sarcoma with Nodal Metastasis
For high-grade undifferentiated pleomorphic sarcoma (UPS) with nodal metastasis, adjuvant anthracycline-based chemotherapy with doxorubicin plus ifosfamide should be strongly considered, as this represents a high-risk scenario where the potential survival benefit outweighs the toxicity risks.
Evidence Supporting Adjuvant Chemotherapy
The evidence base for adjuvant chemotherapy in high-risk soft tissue sarcomas, including UPS with nodal involvement, comes from several key trials and analyses:
High-Risk Patient Selection
Your patient with nodal metastasis falls into the highest-risk category. The most recent guidelines consistently identify that adjuvant chemotherapy is most justified in patients with features predicting high likelihood of relapse: deep location, size >5 cm, high histological grade, and notably, nodal involvement 1. The presence of nodal metastasis significantly elevates risk beyond standard high-grade disease.
Specific Trial Evidence
The Italian Cooperative Study demonstrated the clearest benefit for adjuvant anthracycline-based chemotherapy in high-grade extremity sarcomas. After median follow-up of 59 months, patients receiving epirubicin plus ifosfamide showed significantly improved median disease-free survival (48 vs 16 months) and overall survival (75 vs 46 months), with an absolute OS benefit of 19% at 4 years 2.
The ISG-STS 1001 trial (2025) specifically included UPS patients and demonstrated that anthracycline plus ifosfamide combinations are effective in this histologic subtype, with radiologic response correlating strongly with survival outcomes 3. This is the most recent high-quality evidence directly applicable to UPS.
Meta-Analysis Data
The Sarcoma Meta-Analysis Collaboration (SMAC) remains the highest-quality pooled analysis, using individual patient data with longest follow-up. It demonstrated that doxorubicin-based adjuvant chemotherapy prolongs local and distant recurrence-free survival and overall recurrence-free survival 4. While the overall survival advantage was marginal across all patients, subset analyses revealed significant benefits in high-risk populations.
Critically, a pooled EORTC analysis (n=819) showed that patients with R1 resection margins had significantly improved recurrence-free survival AND overall survival with adjuvant chemotherapy 2. Nodal involvement often correlates with microscopic residual disease risk, making this finding particularly relevant.
Recommended Regimen
The optimal adjuvant regimen for UPS with nodal metastasis is anthracycline plus ifosfamide 1:
- Doxorubicin 75 mg/m² (or epirubicin 120 mg/m²)
- Plus ifosfamide 9-10 g/m² per cycle
- Administered for 3-6 cycles depending on tolerance
- With G-CSF support
UPS is specifically identified as a histologic subtype with greater sensitivity to ifosfamide 1, making combination therapy particularly appropriate rather than single-agent doxorubicin.
Why This Recommendation Despite Mixed Evidence
The guidelines acknowledge that adjuvant chemotherapy is "not standard treatment" across all soft tissue sarcomas 5, 1. However, this reflects the heterogeneity of sarcomas and the modest benefits seen in unselected populations. The key is risk stratification:
- Low-risk patients (G1, <5cm, superficial, R0 resection): No benefit demonstrated
- Intermediate-risk patients: Conflicting evidence, individualized discussion
- High-risk patients (your case with nodal metastasis): Consistent signal of benefit in multiple trials 1, 2
The 2022 SELNET guidelines explicitly state that randomized trials selecting high-risk localized STS with highest dose intensity of anthracyclines and ifosfamide "consistently showed a 5-year OS above 70%" 1. A meta-analysis incorporating these high-dose trials reported statistically significant survival benefit favoring chemotherapy 1.
Critical Caveats
Patient fitness is essential: The regimen requires good performance status to tolerate the toxicity of combination chemotherapy 6, 5
Cardiac function: Cumulative anthracycline dose limits must be respected; baseline cardiac assessment is mandatory 7
Nodal involvement changes the equation: While most adjuvant trials focused on extremity primaries without nodal disease, nodal metastasis represents systemic disease risk comparable to or exceeding other high-risk features
Neoadjuvant may be preferable: If the patient hasn't yet had surgery, neoadjuvant chemotherapy allows assessment of tumor response and may improve resectability 5, 1
Alternative Consideration
If the patient is not fit for combination therapy, single-agent doxorubicin (75 mg/m² every 3 weeks for 4-6 cycles) remains an option, though with lower expected benefit 6, 5.
The most recent 2025 UK guidelines note that immune checkpoint inhibitors show encouraging evidence in UPS 7, and the 2025 Japanese review highlights high response rates with checkpoint inhibitors combined with doxorubicin 8, but these remain investigational in the adjuvant setting and should be considered only within clinical trials.